Article Data

  • Views 740
  • Dowloads 153

Original Research

Open Access

RTKN2, a potential target of breast cancer (BCa), can promote the growth and migration of breast cancer cells

  • Yantao Cai1
  • Wanting Bao1
  • Beili Zhang1,*,

1Department of General Surgery, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, 200011 Shanghai, China

DOI: 10.22514/ejgo.2023.108 Vol.44,Issue 6,December 2023 pp.136-141

Submitted: 31 August 2023 Accepted: 07 October 2023

Published: 15 December 2023

*Corresponding Author(s): Beili Zhang E-mail: Z_beili830@163.com

Abstract

Breast cancer (BCa) is a type of malignancy; however, the exact mechanisms responsible for breast cancer have yet to be elucidated. Rhotekin 2 (RTKN2) is a member of the Rhotekin family. Previous studies demonstrated that RTKN2 is highly expressed in numerous tumors. Previous analysis of the The cancer genome altas (TCGA) database demonstrated that PRKN2 was overexpressed in BCa. However, RTKN2 is rarely reported in BCa and the mechanisms remain unclear. The aim of this study was to elucidate the effect of RTKN2 on the growth of breast cancer cells and investigate the mechanisms involved. Our analysis revealed high expression of RTKN2 in human BCa. The depletion of RTKN2 suppressed the growth of breast cancer cells. In addition, the knockout of RTKN2 restrained the progression of BCa. We also revealed that the knockdown of RTKN2 stimulated cell cycle arrest in BCa. Mechanistically, RTKN2 mediated the Wnt/β-catenin axis to affect the progression of breast cancer. In conclusion, RTKN2 promotes the growth and migration of breast cancer cells by mediating the Wnt/β-catenin axis.


Keywords

Rhotekin 2 (RTKN2); Breast cancer (BCa); Motility; Cell cycle; Wnt/β-catenin axis


Cite and Share

Yantao Cai,Wanting Bao,Beili Zhang. RTKN2, a potential target of breast cancer (BCa), can promote the growth and migration of breast cancer cells. European Journal of Gynaecological Oncology. 2023. 44(6);136-141.

References

[1] Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993–2015: population based observational cohort study. BMJ. 2023; 382: p1744.

[2] Lucarelli AP, Martins MM, Guedes JM. Correlation between the body mass index of patients with breast cancer before and after chemotherapy. European Journal of Gynaecological Oncology. 2017; 38: 187–190.

[3] Huang G, Liang M, Liu H, Huang J, Li P, Wang C, et al. CircRNA hsa_circRNA_104348 promotes hepatocellular carcinoma progression through modulating miR-187-3p/RTKN2 axis and activating Wnt/beta-catenin pathway. Cell Death & Disease. 2020; 11: 1065.

[4] Pang X, Li R, Shi D, Pan X, Ma C, Zhang G, et al. Knockdown of Rhotekin 2 expression suppresses proliferation and induces apoptosis in colon cancer cells. Oncology Letters. 2017; 14: 8028–8034.

[5] Liao J, Dong G, Zhu W, Wulaer B, Mizoguchi H, Sawahata M, et al. Rho kinase inhibitors ameliorate cognitive impairment in a male mouse model of methamphetamine-induced schizophrenia. Pharmacological Research. 2023; 194: 106838.

[6] Ubeysinghe S, Kankanamge D, Thotamune W, Wijayaratna D, Mohan TM, Karunarathne A. Spatiotemporal optical control of Gaq-PLCb interactions. bioRxiv. 2023. [Preprint]

[7] Liao Y, Zeng J, Zhou J, Yang G, Ding K, Zhang X. Silencing of RTKN2 by siRNA suppresses proliferation, and induces G1 arrest and apoptosis in human bladder cancer cells. Molecular Medicine Reports. 2016; 13: 4872–4878.

[8] Wang X, Zhang L, Wang W, Wang Y, Chen Y, Xie R, et al. Rhotekin 2 silencing inhibits proliferation and induces apoptosis in human osteosarcoma cells. Bioscience Reports. 2018; 38: BSR20181384.

[9] Zhao HG, Yin JJ, Chen X, Wu J, Wang W, Tang LW. RTKN2 enhances radioresistance in gastric cancer through regulating the Wnt/b-catenin signalling pathway. Folia Biologica. 2022; 68: 33–39.

[10] Lin Z, Li D, Cheng W, Wu J, Wang K, Hu Y. MicroRNA-181 functions as an antioncogene and mediates NF-kB pathway by targeting RTKN2 in ovarian cancers. Reproductive Sciences. 2019; 26: 1071–1081.

[11] Wei W, Chen H, Liu S. Knockdown of Rhotekin 2 expression suppresses proliferation and invasion and induces apoptosis in hepatocellular carcinoma cells. Molecular Medicine Reports. 2016; 13: 4865–4871.

[12] Derakhshan F, Reis-Filho JS. Pathogenesis of triple-negative breast cancer. Annual Review of Pathology: Mechanisms of Disease. 2022; 17: 181–204.

[13] Jiang YZ, Ma D, Suo C, Shi J, Xue M, Hu X, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell. 2019; 35: 428–440.e425.

[14] Guo Q, Li D, Luo X, Yuan Y, Li T, Liu H, et al. The regulatory network and potential role of LINC00973-miRNA-mRNA ceRNA in the progression of non-small-cell lung cancer. Frontiers in Immunology. 2021; 12: 684807.

[15] Peng B, Ortega J, Gu L, Chang Z, Li GM. Correction: phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3b/Snail signaling pathway. Journal of Biological Chemistry. 2020; 295: 9767.

[16] Nusse R, Clevers H. Wnt/b-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017; 169: 985–999.

[17] Nalli M, Masci D, Urbani A, La Regina G, Silvestri R. Emerging direct targeting b-catenin agents. Molecules. 2022; 27: 7735.

[18] Shang S, Hua F, Hu ZW. The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 2017; 8: 33972–33989.

[19] Li Y, Jin K, van Pelt GW, van Dam H, Yu X, Mesker WE, et al. c-Myb enhances breast cancer invasion and metastasis through the Wnt/b-Catenin/Axin2 pathway. Cancer Research. 2016; 76: 3364–3375.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top